June 17, 2020 / 9:14 PM / 2 months ago

BRIEF-Adamas Provides Program Update For ADS-5102 For Multiple Sclerosis Patients With Walking Impairment

June 17 (Reuters) - Adamas Pharmaceuticals Inc:

* ADAMAS PROVIDES PROGRAM UPDATE FOR ADS-5102 FOR MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT

* ADAMAS PHARMACEUTICALS INC - COMPLETION OF ITS EVALUATION OF ADS-5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT

* ADAMAS PHARMACEUTICALS INC - RECONFIRMS IT WILL NOT INITIATE FURTHER PHASE 3 DEVELOPMENT IN MSW.

* ADAMAS PHARMA - CO’S ENGAGEMENT WITH FDA TO UNDERSTAND POTENTIAL PATH TO SUBMISSION CONFIRMED NEED FOR ADDITIONAL PHASE 3 CONFIRMATORY STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below